<DOC>
	<DOCNO>NCT00656851</DOCNO>
	<brief_summary>We hypothesize heart HIV+ people The Metabolic Syndrome use oxidize fat sugar inappropriately , may impair heart 's ability pump blood . We hypothesize exercise training pioglitazone ( Actos ) improve fat sugar metabolism hearts HIV+ people The Metabolic Syndrome . This study advance understand cardiovascular disease HIV+ people , test efficacy exercise train pioglitazone improve insulin resistance , heart metabolism heart function risk population .</brief_summary>
	<brief_title>Myocardial Function &amp; FFA Metabolism HIV Metabolic Syndrome</brief_title>
	<detailed_description>We hypothesize myocardial free fatty acid glucose utilization oxidation rate dysregulated HIV+ people The Metabolic Syndrome comparison HIV+ people without The Metabolic Syndrome , comparison HIV-seronegative people without The Metabolic Syndrome . We hypothesize dysregulated myocardial fatty acid glucose metabolism associate impaired heart function ( diastolic dysfunction ) HIV+ people The Metabolic Syndrome . We use myocardial positron emission tomography , radioactive isotope tracer palmitate glucose , echocardiography evaluate myocardial metabolism function . HIV+ people The Metabolic Syndrome receive 16wks exercise training pioglitazone ( Actos ) , evaluate potential beneficial effect myocardial metabolism function .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>All participant without metabolic syndrome : 1 . 2850 year old . 2 . Plasma HIV RNA le 5,000 copies/mL previous 3 month OR CD4 count great 100 cells/µL previous 3 month . 3 . Stable least past 3 month HAART regimen . 4 . `` Normal '' blood chemistry least 1 month prior enrollment : platelet count &gt; 50,000/mm3 , absolute neutrophil count &gt; 750/mm3 , liver transaminase &lt; 2.5x upper limit normal ( ULN ) , creatinine &lt; 1.3x ULN , albumin &gt; 30g/L , creatine kinase &lt; 5.9x ULN . Menstruating woman must negative urine betaHCG pregnancy test within 14 day prior study . To control potential metabolic effect alteration female hormone menstrual cycle , menstruate woman study follicular phase ( serum 17betaestradiol &lt; 165 pg/mL ) . 1 . Frank obesity ( BMI &gt; 35kg/m2 ) . 2 . Chronic hepatitis B infection ( HB surface antigen positive ) . Active hepatitis C infection ( detectable Hep C RNA ) . Those cleared hepatitis B C infection eligible . 3 . Diabetes [ fast glucose &gt; 125 mg/dL , fast insulin &gt; 45 µU/mL , 2hr glucose &gt; 200mg/dL ] . 4 . Medications agent regulate glucose metabolism ( e.g. , insulinsensitizers , insulinsecretagogues ) . Lipid lower agent regulate lipid metabolism ( i.e . fibrate , statin ) . 5 . Gestational diabetes , pregnancy , nurse mother . 6 . Serum triglycerides ≥ 500 mg/dL . 7 . Hypogonadism [ total testosterone &lt; 200ng/dL ( men ) &lt; 15ng/dL ( woman ) ] ; thyroid disorder [ TSH &lt; 0.2 &gt; 12µIU/mL ] ; hypercortisolemia [ morning cortisol &gt; 22µg/dL ] . Replacement testosterone thyroid hormone normalize abnormal level acceptable , long treatment blood level stable least 3 month . 8 . Use human growth hormone ( hGH ) GHsecretagogues ( GHreleasing hormonepeptides ) within previous 3 month . 9 . History serious cardiovascular disease ; MI , angina pectoris , heart failure , congenital heart disease , coronary artery disease , coronary artery bypass graft , stroke . Bundle branch block exclusionary limit interpretability resting/exercise ECG . Cardiovascular physical contraindication maximal exercise test cycle ergometer . 10 . Uncontrolled hypertension ( &gt; 140/90 mmHg ) . Certain antihypertensive medication permit ( diuretic , ACE inhibitor ) long medication , dose , blood pressure stable least 3 month . 11 . Welltrained athlete ( define &gt; 3 exercise training exposures/week ; &gt; 30min regimented exercise/exposure maintain least prior 4 week ) . 12 . History active substance abuse ( eg , alcoholism , cocaine , heroin , crack , methamphetamine , phencyclidine ) . 13 . Active secondary infection . Any significant change chronic suppressive therapy opportunistic infection 1 month prior enrollment . 14 . New serious systemic infection 3 week prior enrollment . 15 . History hyperlactatemia lactic acidosis , esp . rapid weight loss . 16 . Debilitatingpainful myopathy neuropathy require 'assistance ' conduct normal activity daily live ( dress , hygiene , prepare meal , operate vehicle ) . These might affect peripheral substrate metabolism . 17 . Chronic renal insufficiency/failure comorbid condition ( eg . cancer , COPD ) alter metabolism . 18 . Pancreatitis , celiac disease , cirrhosis . 19 . Inadequate macronutrient energy intake , malabsorptive disorder . 20 . Dementia condition would prevent voluntary informed consent compliance . 21 . Other compound blind investigational new drug might affect metabolism confound data interpretation ( eg . RU486 , interleukin therapy , cytokinereceptor antagonist ) . 22 . Oral glucocorticoid corticosteroid use within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>28 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Cardiovascular disease risk</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Visceral adiposity</keyword>
	<keyword>treatment experience</keyword>
</DOC>